An Open Label, Multicenter, Non-randomized, Active Controlled, Single Dose Escalation, Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of IN-105 under Fed Conditions in patients with Type 1 Diabetes Mellitus. - TIDM
Phase of Trial: Phase I
Latest Information Update: 25 Jan 2018
At a glance
- Drugs Insulin tregopil (Primary) ; Insulin lispro
- Indications Type 1 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Biocon
- 19 Aug 2010 Planned end date changed from 1 Jul 2010 to 1 Feb 2011 as reported by ClinicalTrials.gov.
- 19 Aug 2010 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 16 Jun 2010 New source identified and integrated (Clinical Trials Registry - India; CTRI2009-091-001008).